1. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(12):e686–725.
2. Katsanos K, Tepe G, Tsetis D, Fanelli F. Standards of practice for superficial femoral and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol. 2014;37(3):592–603.
3. Antonopoulos CN, Mylonas SN, Moulakakis KG, Sergentanis TN, Sfyroeras GS, Lazaris AM, Kakisis JD, Vasdekis SN. A network meta-analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions. J Vasc Surg. 2017;65(1):234–245.e11.
4. Norgren L, Hiatt WR, Dormandy JA, TASC II Working Group, et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26(2):81–157.
5. Mewissen MW. Primary nitinol stenting for femoropopliteal disease. J Endovasc Ther. 2009;16(2 Suppl 2):II63–81.